Beyond generics: Glenmark resets agenda with a bold 10-year pivot to global drug innovation, says chairman Saldanha

“We think we will be an innovative leader in the next 10 years,” said Chairman and General Manager Glenn Saldanha. Mint in an interview. While the company is of the view that the transition is already underway, Saldanha cautioned that the innovation journey is gradual and full of setbacks.